logo

For the Inventor, By the Inventor

Freiburg, Germany

Dr. Falk Pharma Gmbh

Calculating rank
USPTO Granted Patents = 34

% Expired Patents = 29.4



Trademarks = 3

Forward Citations = 362

Loading Chart...
Loading Chart...

38 inventors (with patents filed for the assignee):

goldMedal Rudolf Wilhelm (13 out of 13 patents)

silverMedal Roland Greinwald (12 out of 12 patents)

bronzeMedal Norbert Otterbeck (10 out of 10 patents)

4.  Markus Proels (6 out of 6 patents)

5.  Markus Pröls (6 out of 6 patents)

6.  Ralph Mueller (4 out of 4 patents)

7.  Ralf Mohrbacher (4 out of 4 patents)

8.  Peter Gruber (4 out of 13 patents)

9.  Rudolph Wilhelm (3 out of 3 patents)

10.  Bernhard Tewes (3 out of 3 patents)

11.  Tanju Nacak (2 out of 2 patents)

12.  Wolfgang Mohr (2 out of 7 patents)

13.  Mark Renshaw (2 out of 10 patents)

14.  Erik Fischer (2 out of 2 patents)

15.  Heidi Waenerlund Poulsen (2 out of 2 patents)


Core Competencies:
Pyridinone Derivatives
Coeliac Disease
Anti-CD30L Antibodies
Inflammatory Bowel Disease
Budesonide
Nor-Ursodeoxycholic Acid
Pellet Formulation
Mesalazine
Rectal Application
Liver Fat Reduction
Crystalline Bile Acids

34 patents:

1. 12661348 - Systemic formulation of a pyridinone derivate for TG2-related diseases (2026-06-23),
2. 12661347 - Systemic formulation of a pyridinone derivate for coeliac disease (2026-06-23),
3. 12516126 - ANTI-CD30L ANTIBODIES AND USES THEREOF (2026-01-06),
4. 12472191 - Pharmaceutical formulation for the treatment of inflammatory changes to the rectum (2025-11-18),
5. 12459906 - 3-(5-chloro-2-oxobenzo[d]oxazol-3(2H)-yl) propanoic acid derivatives as KMO inhibitors (2025-11-04),
6. 12064509 - Enema for rectal application (2024-08-20),
7. 11866505 - Anti-CD30L antibodies and uses thereof (2024-01-09),
8. 11850252 - Use of nor-ursodeoxycholic acid for reducing liver fat (2023-12-26),
9. 11738032 - Pharmaceutical formulation for the treatment of inflammatory changes to the rectum (2023-08-29),
10. 11464733 - Enema for rectal application (2022-10-11),
11. 11382860 - Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus (2022-07-12),
12. 11173121 - Pellets having a multi-layer structure for delayed release of the active substance in the distal colon (2021-11-16),
13. 11135159 - Optimized high-dose mesalazine-containing tablet (2021-10-05),
14. 10905699 - Pharmaceutical formulation for the treatment of inflammatory changes to the rectum (2021-02-02),
15. 10695291 - Optimized pharmaceutical formulation for the treatment of inflammatory conditions of the esophagus (2020-06-30),
Company Overview
Dr. Falk Pharma GmbH is a prominent pharmaceutical company based in Freiburg, Germany, specializing in the development and commercialization of innovative therapies for gastrointestinal and liver diseases. The company focuses on providing high-quality medications and solutions that address unmet medical needs, leveraging advanced research and development capabilities. With a commitment to improving patient outcomes, Dr. Falk Pharma collaborates with healthcare professionals and institutions to enhance treatment options in its specialized fields.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

Dr. Falk Pharma Gmbh USPTO Patent Assignee Logo
34 Patents

#13 in Freiburg

#1,454 in Germany

#19,664 in the World

Freiburg, DE
Freiburg, Germany

Dr. Falk Pharma Gmbh

Forward Citations = 362

38 inventors:

goldMedal Rudolf Wilhelm (13 out of 13 patents)

silverMedal Roland Greinwald (12 out of 12 patents)

bronzeMedal Norbert Otterbeck (10 out of 10 patents)

4.  Markus Proels (6 out of 6 patents)

5.  Markus Pröls (6 out of 6 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Dr. Falk Pharma Gmbh. Retrieved from https://idiyas.com/company/dr-falk-pharma

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…